Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
971 articles by Jacob Bell
-
Roche wagers $1.4B that Promedior has its next big fibrosis drug
Nov. 15, 2019 -
Merck wants to know if taking out cellular trash can treat Alzheimer's
Nov. 13, 2019 -
Reata's kidney data gets a tepid response from investors
Nov. 12, 2019 -
CF Foundation puts half a billion dollars toward drugs for all patients
Oct. 30, 2019 -
What to make of Gilead's latest NASH deal
Oct. 28, 2019 -
Pharmacquired: Eylea could be in trouble, but that doesn't make Regeneron a buyer
Oct. 25, 2019 -
Vertex clears its biggest commercial hurdle: UK insurance coverage
Oct. 24, 2019 -
In major surprise, Biogen will ask FDA to approve Alzheimer's drug aducanumab
Oct. 22, 2019 -
Vertex wins speedy approval for cystic fibrosis triplet
Oct. 21, 2019 -
GSK hands 2 of its less profitable vaccines to Bavarian Nordic
Oct. 21, 2019 -
Alexion bids for a smaller version of itself, spurring concerns about the FTC
Oct. 16, 2019 -
Reata surprises with positive data in challenging rare disease
Oct. 15, 2019 -
Five Prime's restructuring claims more jobs
Oct. 11, 2019 -
UCB bets more on rare disease drugs with Ra Pharma acquisition
Oct. 10, 2019 -
Eylea casts a shadow over Novartis' latest approval
Oct. 8, 2019 -
After more than a year, Gilead finds new chief medical officer
Oct. 7, 2019 -
Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion
Oct. 4, 2019 -
Gene therapy stocks have taken a beating. Their recovery may be slow
Oct. 3, 2019 -
Biogen's R&D head is out, following string of clinical setbacks
Oct. 1, 2019 -
Sobi finds another fit for its dealmaking strategy
Sept. 30, 2019 -
Pfizer's new JAK drug works, but class safety concerns linger
Sept. 27, 2019 -
Investors conclude there are probably better NASH drugs than Enanta's
Sept. 26, 2019 -
Alder's migraine drug attracted plenty of dealmakers. The company, not so much
Sept. 24, 2019 -
Cancer centers stretching to keep up with pharma's oncology interest
Sept. 23, 2019 -
Merck, Pfizer execs explain how they tap sites for cancer trials
Sept. 23, 2019